1-3 of 3
Kris Poulsen
Close
Sort by
Journal Articles

Preclinical Evaluation of ALLO-819, an Allogeneic CAR T Cell Therapy Targeting FLT3 for the Treatment of Acute Myeloid Leukemia

Cesar Sommer, PhD, Hsin-Yuan Cheng, PhD, Yik Andy Yeung, PhD, Duy Nguyen, Janette Sutton, Zea Melton, Julien Valton, PhD, Kris Poulsen, Ivana Djuretic, PhD, Thomas Van Blarcom, PhD, Javier Chaparro-Riggers, PhD, Barbra Sasu, PhD
Journal: Blood
Blood (2019) 134 (Supplement_1): 3921.
https://doi.org/10.1182/blood-2019-129025
Published: 2019
Journal Articles

ALLO-819, an Allogeneic Flt3 CAR T Therapy Possessing an Off-Switch for the Treatment of Acute Myeloid Leukemia

Cesar Sommer, PhD, Ivana Djuretic, PhD, Julien Valton, PhD, Duy Nguyen, Janette Sutton, Kris Poulsen, Julianne Smith, PhD, Ivana Djuretic, PhD, Javier Chaparro-Riggers, PhD, Barbra Sasu, PhD
Journal: Blood
Blood (2018) 132 (Supplement 1): 3335.
https://doi.org/10.1182/blood-2018-99-117605
Published: 2018
Journal Articles

A Novel Full Length Anti-FLT3 CD3 Bispecific Antibody for the Treatment of Acute Myeloid Leukemia

Ivana Djuretic, PhD, Veena Krishnamoorthy, PhD, Cesar Sommer, PhD, Danielle E. Dettling, Kris Poulsen, Wei Chen, PhD, Wenyue Hu, PhD, Allison Given Chunyk, Kevin Lindquist, Shobha Potluri, PhD, Robert C Rickert, PhD, Barbra Sasu, PhD, Javier Chaparro-Riggers, PhD, Yik Andy Yeung, PhD
Journal: Blood
Blood (2018) 132 (Supplement 1): 1445.
https://doi.org/10.1182/blood-2018-99-119915
Published: 2018